MX2023011502A - Proteina de fusion inmunogenica. - Google Patents
Proteina de fusion inmunogenica.Info
- Publication number
- MX2023011502A MX2023011502A MX2023011502A MX2023011502A MX2023011502A MX 2023011502 A MX2023011502 A MX 2023011502A MX 2023011502 A MX2023011502 A MX 2023011502A MX 2023011502 A MX2023011502 A MX 2023011502A MX 2023011502 A MX2023011502 A MX 2023011502A
- Authority
- MX
- Mexico
- Prior art keywords
- acid sequence
- amino acid
- amino acids
- fusion protein
- immunogenic fusion
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 title abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 8
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 7
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 241000193990 Streptococcus sp. 'group B' Species 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21165674.9A EP4066854A1 (en) | 2021-03-29 | 2021-03-29 | Immunogenic fusion protein |
| PCT/EP2022/058309 WO2022207657A1 (en) | 2021-03-29 | 2022-03-29 | Immunogenic fusion protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011502A true MX2023011502A (es) | 2023-10-19 |
Family
ID=75277909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011502A MX2023011502A (es) | 2021-03-29 | 2022-03-29 | Proteina de fusion inmunogenica. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240173394A1 (enExample) |
| EP (2) | EP4066854A1 (enExample) |
| JP (1) | JP2024512722A (enExample) |
| KR (1) | KR20230163500A (enExample) |
| CN (1) | CN117120081A (enExample) |
| AU (1) | AU2022248869A1 (enExample) |
| BR (1) | BR112023019757A2 (enExample) |
| CA (1) | CA3212987A1 (enExample) |
| IL (1) | IL307256A (enExample) |
| MX (1) | MX2023011502A (enExample) |
| WO (1) | WO2022207657A1 (enExample) |
| ZA (1) | ZA202309225B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4553166A1 (en) | 2023-11-07 | 2025-05-14 | MinervaX ApS | Method for preparing a sample for analysis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL107458A0 (en) | 1992-11-02 | 1994-02-27 | Gen Hospital Corp | Conjugate vaccine against group b streptococcus |
| PT656014E (pt) | 1993-03-19 | 2003-09-30 | Gunnar Lindahl | Proteina rib, uma proteina da superficie celular que confere imunidade a muitas estirpes de estreptococos do grupo b: processo para purificacao da proteina, estojo de reagentes e composicao farmaceutica |
| US6426074B1 (en) | 1997-03-19 | 2002-07-30 | The Brigham And Women's Hospital Inc. | Group B Streptococcus vaccine |
| PT2144924T (pt) * | 2007-04-16 | 2016-08-17 | Minervax Aps | Vacina de proteína de fusão |
| EP3365003A1 (en) * | 2015-10-21 | 2018-08-29 | Minervax APS | Immunogenic fusion protein |
| WO2017114655A1 (en) * | 2015-12-30 | 2017-07-06 | Minervax Aps | Immunogenic complex for eliciting protective immunity against group b streptococcus |
-
2021
- 2021-03-29 EP EP21165674.9A patent/EP4066854A1/en not_active Withdrawn
-
2022
- 2022-03-29 CA CA3212987A patent/CA3212987A1/en active Pending
- 2022-03-29 CN CN202280027427.3A patent/CN117120081A/zh active Pending
- 2022-03-29 JP JP2023560549A patent/JP2024512722A/ja active Pending
- 2022-03-29 US US18/284,513 patent/US20240173394A1/en active Pending
- 2022-03-29 EP EP22713429.3A patent/EP4313134A1/en active Pending
- 2022-03-29 IL IL307256A patent/IL307256A/en unknown
- 2022-03-29 BR BR112023019757A patent/BR112023019757A2/pt unknown
- 2022-03-29 AU AU2022248869A patent/AU2022248869A1/en active Pending
- 2022-03-29 KR KR1020237037124A patent/KR20230163500A/ko active Pending
- 2022-03-29 MX MX2023011502A patent/MX2023011502A/es unknown
- 2022-03-29 WO PCT/EP2022/058309 patent/WO2022207657A1/en not_active Ceased
-
2023
- 2023-10-02 ZA ZA2023/09225A patent/ZA202309225B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4313134A1 (en) | 2024-02-07 |
| AU2022248869A1 (en) | 2023-10-26 |
| WO2022207657A1 (en) | 2022-10-06 |
| ZA202309225B (en) | 2025-03-26 |
| BR112023019757A2 (pt) | 2023-10-31 |
| IL307256A (en) | 2023-11-01 |
| JP2024512722A (ja) | 2024-03-19 |
| US20240173394A1 (en) | 2024-05-30 |
| EP4066854A1 (en) | 2022-10-05 |
| AU2022248869A9 (en) | 2023-11-09 |
| KR20230163500A (ko) | 2023-11-30 |
| CA3212987A1 (en) | 2022-10-06 |
| CN117120081A (zh) | 2023-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022043551A3 (en) | Multivalent nucleic acid based coronavirus vaccines | |
| Babapoor et al. | A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection | |
| JP2015214545A5 (enExample) | ||
| SI2280721T1 (en) | Indoleamine 2, 3-dioxygenase based immunotherapy | |
| JP2019504030A5 (enExample) | ||
| RU2014134365A (ru) | Вакцины против clostridium difficile, включающие рекомбинантные токсины | |
| ES2586418T3 (es) | Vacuna de proteína de fusión | |
| RU2018116601A (ru) | Иммунногенный слитый белок | |
| DK3072523T3 (en) | COMPOSITION FOR PREVENTION AND TREATMENT OF INFECTIONS WITH MYCOPLASMA | |
| WO2023042099A3 (en) | Vaccines for coronavirus prevention and treatment | |
| AR079712A1 (es) | Composiciones inmunogenicas; kit y vacuna | |
| RU2018122755A (ru) | Слитые белки fmdv-e2 и их применение | |
| MX2025010274A (es) | Composiciones para su uso en el tratamiento de clamidia | |
| ZA202309225B (en) | Immunogenic fusion protein | |
| RU2019115303A (ru) | Вакцинные конструкты и их применения против инфекций стафилококка | |
| AR100824A1 (es) | Complejo de poliproteínas inmunogénicas de m. hyopneumoniae, gen sintético codificante del complejo de proliproteínas inmunogénicas de m. hyopneumoniae, composición antigénica, proceso de obtención de un complejo de poliproteínas inmunogénicas de m. hyopneumoniae, uso de una composición con base en el complejo de poliproteínas inmunogénicas de m. hyopneumoniae | |
| MX2025013140A (es) | Composiciones para el uso en el tratamiento del acne | |
| AR127169A1 (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| WO2005083072A1 (ja) | 大腸菌における豚丹毒菌表層防御抗原変異体の製造方法 | |
| US9889192B2 (en) | Immunization with rabies virus vector expressing foreign protein antigen | |
| WO2014045084A1 (es) | Proteínas de fusión con representación de diferentes alergenos: propuesta de vacuna para alergia a los ácaros | |
| JP2024512722A5 (enExample) | ||
| MX2020001055A (es) | Vacuna contra la malaria. | |
| CN1909925B (zh) | 一种免疫佐剂 | |
| WO2014185817A3 (ru) | Вакцина для профилактики и лечения ротавирусной инфекции, содержащая гибридный белок в качестве активного агента (варианты) |